Safety and Efficacy of Statin Therapy for Primary CVD Prevention in Diabetic Populations

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Annals of Internal Medicine, https://doi.org/10.7326/ANNALS-25-00662 
Dr. Vincent Ka Chun Yan  et al.

Points

Researchers evaluated the effectiveness of starting statin therapy for primary prevention among adults with type 2 diabetes by analyzing a large database of clinical records from the United Kingdom.
The study population consisted of patients between twenty-five and eighty-four years of age who did not have a history of serious heart or liver conditions before the analysis began.
Findings demonstrated that statins successfully lowered the risk of all-cause mortality and reduced major adverse cardiac events for every risk group including those with low predicted ten-year cardiovascular risk.
Safety assessments revealed a minimal increase in the incidence of myopathy in one risk category while confirming that there was no added risk of liver issues for these patients.
These results suggest that clinicians should consider the long-term protective benefits of statins for all adults with type 2 diabetes regardless of their initial short-term predicted cardiovascular disease risk.

Summary

This target trial emulation study, published in Annals of Internal Medicine, evaluated the effectiveness and safety of statin initiation for primary prevention in adults with type 2 diabetes (T2DM). Researchers from the University of Hong Kong utilized the IQVIA Medical Research Data (IMRD)-UK database to analyze a cohort of patients aged 25 to 84 years without prior history of serious heart or liver disease. The participants were stratified by their predicted 10-year risk of cardiovascular disease (CVD) and followed for up to 10 years to assess clinical outcomes.

The analysis demonstrated that statin initiation was associated with a significant reduction in all-cause mortality and major adverse cardiac events across all risk strata. Notably, the data indicated that these protective benefits extended even to patients categorized as having a low predicted 10-year CVD risk, a group for whom preventive therapy has historically been a subject of clinical uncertainty. These findings suggest that the metabolic environment of T2DM may necessitate broader pharmacological intervention than current risk-based models typically suggest.

In terms of safety, the researchers reported a very small increase in the incidence of myopathy within a single risk group, though no overall added risk for liver complications was observed. The results indicate that the survival and cardiovascular benefits of statin use outweigh potential adverse effects across the entire risk spectrum. Consequently, the authors suggest that clinicians consider the initiation of statins for all adults with type 2 diabetes, regardless of whether their short-term predicted cardiovascular risk is low.

Link to the article: https://www.acpjournals.org/doi/10.7326/ANNALS-25-00662

References

Yan, V. K. C., Blais, J. E., Gamble, J.-M., Chan, E. W. Y., Wong, I. C. K., & Wan, E. Y. F. (2025). Effectiveness and safety of statins in type 2 diabetes according to baseline cardiovascular risk: A target trial emulation study. Annals of Internal Medicine, ANNALS-25-00662. https://doi.org/10.7326/ANNALS-25-00662